Previous
Next
Previous
Next

PANCREATIC CANCER PROGNOSIS & SURVIVAL

Each year more than 50,000 people in the United States (and double this number in Europe) are now diagnosed with pancreatic cancer (adenocarcinoma). The prognosis is such that most of these people will have passed by the end of the first year. In the U.S., pancreatic cancer is 9th or 10th most commonly diagnosed cancer (depending on gender), but the fourth leading cause of cancer death in men and women.

The prognosis of pancreatic cancer (adenocarcinoma of the pancreas) is a very tough, though the survival rates have been incrementally improving particularly over the past ten to fifteen years. It is important to realize that each person is individual; each cancer is different. Statistics can only indicate what tends to happen in the aggregate, and not in the case of an individual person.

The median survival duration from the time of diagnosis until demise is arguably the worst of any of the cancers – certainly of the major cancers. The median survival for untreated advanced pancreatic cancer is about 3 1/2 months; with good treatment this increases to about eight months, though many will live much longer. We have encountered nine and eleven and twelve  year survivors.

Perhaps it is a good place to discuss what the term median means. Simply put, the median is the time point that separates half of patients who live longer from the half who will live less. Thus, there are many patients who will live much longer than the median.

The American Cancer Society prognosis figures show that the stage at which pancreatic cancer is diagnosed is strongly correlated to survival; earlier obviously being better. But, the statistics are still pretty tough. The five year survival rate with good treatment is now considered to be about 8%.  Again, it is imperative to understand that each person’s situation individual; each cancer is different. Statistics can only indicate what tends to happen in the aggregate, and not in the case of an individual person. Many people do better than average.

The prognosis for those who are able to have surgery is improved over those who are not able. Unfortunately, only about 15% of those individuals with pancreatic cancer will be found to be eligible for surgery – for most, the cancer will have been found to be too advanced. For example, patients with pancreatic cancer who received the Whipple surgical procedure in one study (from a very experienced Johns Hopkins team) were reported as having a 21% five-year survival rate, with a median survival of 15.5 months. In more recent studies this five-year median survival duration after surgery has been reported as high as twenty months.

The prognosis is also better for those whose pancreatic cancer is diagnosed at an earlier stage. The median survival duration from diagnosis with chemotherapy medical treatment in locally advanced cancer of the pancreas has been reported as 6 to 12 months.

Patients with neuroendocrine tumors tend to have a much more favorable prognosis than, for example, those with adenocarcinoma of the pancreas. The natural history of neuroendocrine tumors, islet cell tumors, and carcinoid tumors tends to be very different than that of pancreatic adenocarcinoma. For example, the median survival duration from the time of diagnosis for patients with non-functioning metastatic islet cell tumors approaches five years.

pancreatic cancer research

ABSTRACTS:

The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic. These abstracts can be searched Here.

  • 1-Oct-16 – Prognostic factors for those treated with Gemzar 
  • 1-Oct-16 – Prognosis schema for advanced pancreatic cancer 
  • 28-Jul-16 – Standard factors for prognosis in pancreatic cancer surgery 
  • 1-Jul-15 – mRNAs for prognosis of cancer of the pancreas 
  • 1-Nov-13 – Long Duration Survivors with Cancer of the Pancreas  – Are they There?
  • 1-Jan-13 – Prognosis of Early Stage Cancer of the Pancreas
  • 1-Jun-12 – Prognostic Advantage of Ajduvant Treatment of Pancreatic Adenocarcinoma
  • 1-Jun-12 – Resection and Prognosis of Pancreatic Tumors
  • 1-Mar-12 – Treatment and Prognosis of Cancer of the Pancreas
  • 1-Mar-12 – Prognosis of Pancreatic Cancer – the Chemoradiotherapy Controversy
  • 28-Feb-12 – Gemcitabine vs. FOLFIRINOX Regimens: Prognosis
  • 1-Feb-12 – Chemoradiation Plus Induction Chemo for Locally Advanced Cancer of the Pancreas
  • 1-Dec-11 – Survival Statistics for Neoadjuvant Therapy
  • 1-Nov-11 – Prognosis of IPMN
  • 1-Jul-11 – The Promise of FOLFIRINOX: Improved prognosis
  • 1-May-11 – Better Prognosis: 5-FU Combination Therapy

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology Duke University

Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University

Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco

Our Philosophy About Pancreatic Cancer

Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.

We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.

That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.

Facebook Fundraising is Easy!

Creating a Facebook Fundraiser is easy: Click the Link below and Facebook will take you through the steps! Dedicate your Birthday or another important date to honor a loved one.
MAKE IMPACT

SIGN UP FOR THE LATEST NEWS ABOUT PANCREATIC CANCER, WAYS TO HELP, AND MORE!

To Safely make a Donation via Text, Text the Code FIGHTPC to number 44-321

Making IMPACT for Pancreatic Cancer Together!

Join our expanding community on Facebook! Connect with others, share stories, and get support! Click Here

MONTHLY MEMORIAL GIFTS: YOUR TRIBUTE TO A LOVED ONE

Regular giving can be an opportunity to pay tribute in honour of a loved one. Your monthly gift will go directly to promoting awareness, increasing education, furthering pancreatic cancer research aimed at early diagnosis and, helping patients and families impacted by the effects of pancreatic cancer.

Simply select “Monthly” after choosing the amount you would like to give.

Genetic Testing for Pancreatic Cancer

PROPOSED: Every newly diagnosed person with pancreatic cancer (ductal adenocarcinoma of the pancreas) should receive genetic screening prior to beginning treatment – to test for germline genetic mutations in the homologous recombination DNA repair pathway, including genes such as BRCA1, BRCA2, PALB2, and others. These results, in from 12% to 17% of pancreatic cancer patients, suggest that treatment that includes DNA cross-linking agents such as platinum compounds or PARP inhibitors may be superior to standard best practices therapy.


OFFER: Color Genomics offers a 30-gene cancer panel for $224 (normally $249) when the Promotion Code “PANCREATIC” is entered at checkout (price will reduce upon entering this code). This is a physician-ordered saliva kit. Click Here for more information

RATIONALE: The age of precision medicine in pancreatic cancer is approaching … [MORE]

This year an estimated 57,600 Americans will be diagnosed with pancreatic cancer. Approximately 47,050 Americans are expected to die from the disease. There are many reasons why the outcome for pancreatic cancer patients is bleaker than for most other cancer types. There are no reliable methods to detect the disease early, and there are very few effective treatment options. Which is why we are so focused on supporting research for early diagnosis.

Together with You our Mission is to promote awareness, increase education, and further pancreatic cancer research aimed at early diagnosis.

Most of our fundraisers, supporters, and volunteers, have been in one way or another, personally effected by this disease. We want to acknowledge what hardships you may have gone through (or are currently facing) and sincerely thank you for visiting our site!

Walk, Run, or Choose your own!

Choose a walk, run, or any other activity that you like and work to raise donations leading up to your Event! Simply set up your participation page and we will be in touch!

DEDICATE YOUR RACE

Already registered for your next Race? Dedicate your participation to Pancreatic Cancer. Simply set up your participation page and together we will work towards our shared mission!

ON FACEBOOK​

Creating a Facebook Fundraiser is easy: Click the Link below and Facebook will take you through the steps! Dedicate your Birthday or another important date to honor a loved one.

CREATE YOUR OWN FUNDRAISER

Create your own fun, choose something you already love to support pancreatic cancer! Simply set up your participation page, include the details of your fundraiser on your page, and get the word out!

Cancer Patients Alliance is a 501(c)(3) non-profit. Initiatives include, ToFightCancer.com and Pancreatica.org. All Donations are tax-deductible.

Pancreatic cancer is expected to become the 2nd leading cause of cancer-related death by the year 2020. There are many reasons why the outcome for pancreatic cancer patients is much bleaker than for most other cancer types. There are no reliable methods to detect the disease early, and there are very few effective treatment options.

There remains a dire need for more research and an increase in focused funding for pancreatic cancer. Your Donation will go directly to promoting awareness, increasing education, and furthering pancreatic cancer research aimed at early diagnosis.

Amazon donates 0.5% of the price of your eligible AmazonSmile purchases to help fight pancreatic cancer!
AmazonSmile is the same Amazon you know. Same products, same prices, same service. Simply use our Link to start shopping!

Best of the Blog

Speak with a Survivor:

Call 1-800-433-0464 for a free service that will place you in contact with a fellow survivor, or to volunteer to contact someone more recently diagnosed.


Pancreatic Cancer Blog

One of the observations that physicians often made when the standard of care treatment typically consisted of the chemotherapy drug agent of gemcitabine alone, was that many patients with pancreatic cancer (ductal adenocarcinoma of the pancreas) seemed to feel better after the initiation of treatment… More Here

 

Join us on Social Media !

Pay tribute to your Loved one.

Honor a Loved One with a Monthly Gift!